688166 (BrightGene Bio-Medical Technology Co Ltd) vs Shanghai Composite Comparison

688166

Shanghai Composite

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

688166

Shanghai Composite

Difference

1Y 3Y 5Y 10Y 15Y 20Y

688166

Shanghai Composite

Add Stock

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Shanghai Composite

688166

LLY

DPH

NOVO B

JNJ

Add Stock

1Y 3Y 5Y 10Y 15Y 20Y

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

BrightGene Bio-Medical Technology Co Ltd
Glance View

Market Cap

12.5B CNY

Industry

Pharmaceuticals

BrightGene Bio-Medical Technology Co., Ltd. emerges as a compelling player in the pharmaceutical landscape, weaving innovation with strategic execution. Specializing in the research, development, and manufacturing of high-quality generic drugs and pharmaceutical intermediates, the company finds its niche at the intersection of science and commerce. Founded with a vision to leverage cutting-edge technologies for developing advanced therapeutic solutions, BrightGene has carved a significant space in both domestic and international markets. Its state-of-the-art facilities reflect a commitment to rigorous quality standards and continual improvement, aligning with its mission to deliver cost-effective healthcare solutions. At the heart of BrightGene's business model is its robust pipeline of generic pharmaceutical products, which it advances from concept to commercialization. The company monetizes its innovations by licensing and supplying active pharmaceutical ingredients (APIs) and finished dosage forms to global partners, including major pharmaceutical companies. This collaborative approach ensures a steady flow of revenue through licensing agreements and joint ventures, positioning BrightGene as not just a manufacturer, but a valued partner in the quest for affordable healthcare. By continuously expanding its product portfolio and refining manufacturing processes, BrightGene sustains its growth trajectory, capitalizing on a market hungry for cost-efficient, high-quality generic medications.

View BrightGene Bio-Medical Technology Co Ltd Analysis

Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	Add
US		Eli Lilly and Co NYSE:LLY	Add
UK		Dechra Pharmaceuticals PLC LSE:DPH	Add
DK		Novo Nordisk A/S CSE:NOVO B	Add
US		Johnson & Johnson NYSE:JNJ	Add
US		Merck & Co Inc NYSE:MRK	Add
CH		Roche Holding AG SIX:ROG	Add
UK		AstraZeneca PLC LSE:AZN	Add
CH		Novartis AG SIX:NOVN	Add
US		Pfizer Inc NYSE:PFE	Add

JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	Select
US		Eli Lilly and Co NYSE:LLY	Select
UK		Dechra Pharmaceuticals PLC LSE:DPH	Select
DK		Novo Nordisk A/S CSE:NOVO B	Select
US		Johnson & Johnson NYSE:JNJ	Select
US		Merck & Co Inc NYSE:MRK	Select
CH		Roche Holding AG SIX:ROG	Select
UK		AstraZeneca PLC LSE:AZN	Select
CH		Novartis AG SIX:NOVN	Select
US		Pfizer Inc NYSE:PFE	Select

JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	Add
US		Eli Lilly and Co NYSE:LLY	Add
UK		Dechra Pharmaceuticals PLC LSE:DPH	Add
DK		Novo Nordisk A/S CSE:NOVO B	Add
US		Johnson & Johnson NYSE:JNJ	Add
US		Merck & Co Inc NYSE:MRK	Add
CH		Roche Holding AG SIX:ROG	Add
UK		AstraZeneca PLC LSE:AZN	Add
CH		Novartis AG SIX:NOVN	Add
US		Pfizer Inc NYSE:PFE	Add

CA	A	Advance Lithium Corp XTSX:AALI	Add
US	G	GE Vernova LLC NYSE:GEV	Add
NL	N	Nepi Rockcastle NV JSE:NRP	Add
US		Schlumberger NV NYSE:SLB	Add
US	B	Baker Hughes Co NASDAQ:BKR	Add
ID		Amman Mineral Internasional Tbk PT IDX:AMMN	Add
US	R	Reddit Inc NYSE:RDDT	Add
CH	G	Galderma Group AG SIX:GALD	Add
US		Halliburton Co NYSE:HAL	Add
IN		Jio Financial Services Ltd NSE:JIOFIN	Add

	Franklin Covey Co NYSE:FC	35.24 USD -2.49%
	Mohawk Industries Inc NYSE:MHK	117.3 USD -0.4%
	Ardmore Shipping Corp NYSE:ASC	12.77 USD 5.54%
	ASGN Inc NYSE:ASGN	86.34 USD 1.25%
	Skyworks Solutions Inc NASDAQ:SWKS	92.66 USD 1.93%
	Weatherford International PLC NASDAQ:WFRD	74.8 USD 1.75%

688166

vs

Shanghai Composite

Stocks Performance
688166 vs Shanghai Composite

Performance Gap
688166 vs Shanghai Composite

Performance By Year
688166 vs Shanghai Composite

Competitors Performance
BrightGene Bio-Medical Technology Co Ltd vs Peers

BrightGene Bio-Medical Technology Co Ltd
Glance View

Company

Help

Tools

Stocks

	Johnson & Johnson NYSE:JNJ	146.23 USD 1.79%
	Bank of America Corp NYSE:BAC	46.08 USD 1.5%
	Mastercard Inc NYSE:MA	511.4 USD -0.1%
	Salesforce Inc NYSE:CRM	324.93 USD -1.69%
	Abbvie Inc NYSE:ABBV	179.53 USD -0.32%
	Home Depot Inc NYSE:HD	384.23 USD -1.32%

	Arista Networks Inc NYSE:ANET	115.29 USD -3.1%
	Visa Inc NYSE:V	311.67 USD -0.44%
	Texas Pacific Land Corp NYSE:TPL	1 258.29 USD 2.58%
	KLA Corp NASDAQ:KLAC	689.3 USD -0.14%
	Manhattan Associates Inc NASDAQ:MANH	268.2 USD -1.16%
	Pinduoduo Inc NASDAQ:PDD	100.62 USD 1.62%

	Salesforce Inc NYSE:CRM	324.93 USD -1.69%
	ServiceNow Inc NYSE:NOW	1 054.15 USD -2.13%
	EOG Resources Inc NYSE:EOG	127.56 USD 0.93%
	Copart Inc NASDAQ:CPRT	56.24 USD -0.6%
	Applied Materials Inc NASDAQ:AMAT	177.82 USD 0.19%
	Synopsys Inc NASDAQ:SNPS	487.62 USD -2.68%

	Johnson & Johnson NYSE:JNJ	146.23 USD 1.79%
	Berkshire Hathaway Inc NYSE:BRK.A	678 560 USD 0.29%
	Bank of America Corp NYSE:BAC	46.08 USD 1.5%
	Mastercard Inc NYSE:MA	511.4 USD -0.1%
	UnitedHealth Group Inc NYSE:UNH	514.25 USD 0.11%
	Exxon Mobil Corp NYSE:XOM	108.75 USD 0.94%

688166 vs Shanghai Composite

Stocks Performance 688166 vs Shanghai Composite

Performance Gap 688166 vs Shanghai Composite

Performance By Year 688166 vs Shanghai Composite

Competitors Performance BrightGene Bio-Medical Technology Co Ltd vs Peers

BrightGene Bio-Medical Technology Co Ltd Glance View

Company

Help

Tools

Stocks

688166

vs

Shanghai Composite

Stocks Performance
688166 vs Shanghai Composite

Performance Gap
688166 vs Shanghai Composite

Performance By Year
688166 vs Shanghai Composite

Competitors Performance
BrightGene Bio-Medical Technology Co Ltd vs Peers

BrightGene Bio-Medical Technology Co Ltd
Glance View